IL312427B2 - פורמולציות פמטרקסד - Google Patents
פורמולציות פמטרקסדInfo
- Publication number
- IL312427B2 IL312427B2 IL312427A IL31242724A IL312427B2 IL 312427 B2 IL312427 B2 IL 312427B2 IL 312427 A IL312427 A IL 312427A IL 31242724 A IL31242724 A IL 31242724A IL 312427 B2 IL312427 B2 IL 312427B2
- Authority
- IL
- Israel
- Prior art keywords
- pemetrexed formulations
- pemetrexed
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/018703 WO2017142556A1 (en) | 2016-02-19 | 2016-02-19 | Pemetrexed formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL312427A IL312427A (he) | 2024-06-01 |
| IL312427B1 IL312427B1 (he) | 2025-12-01 |
| IL312427B2 true IL312427B2 (he) | 2026-04-01 |
Family
ID=59625349
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312427A IL312427B2 (he) | 2016-02-19 | 2016-02-19 | פורמולציות פמטרקסד |
| IL301291A IL301291A (he) | 2016-02-19 | 2016-02-19 | ניסוחים פמטרקס |
| IL261179A IL261179B (he) | 2016-02-19 | 2018-08-15 | פורמולציות של פמטרקסד |
| IL290647A IL290647B2 (he) | 2016-02-19 | 2022-02-15 | ניסוחים פמטרקס |
| IL324306A IL324306A (he) | 2016-02-19 | 2025-10-28 | פורמולציות פמטרקסד |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301291A IL301291A (he) | 2016-02-19 | 2016-02-19 | ניסוחים פמטרקס |
| IL261179A IL261179B (he) | 2016-02-19 | 2018-08-15 | פורמולציות של פמטרקסד |
| IL290647A IL290647B2 (he) | 2016-02-19 | 2022-02-15 | ניסוחים פמטרקס |
| IL324306A IL324306A (he) | 2016-02-19 | 2025-10-28 | פורמולציות פמטרקסד |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3416646A4 (he) |
| JP (1) | JP2019505561A (he) |
| KR (2) | KR102794126B1 (he) |
| CN (1) | CN109152778B (he) |
| AU (3) | AU2016393213B2 (he) |
| CA (1) | CA3014755C (he) |
| IL (5) | IL312427B2 (he) |
| MX (2) | MX2022009547A (he) |
| WO (1) | WO2017142556A1 (he) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080139810A1 (en) * | 2006-08-14 | 2008-06-12 | Jonathan Busolli | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid |
| WO2013179248A1 (en) * | 2012-05-30 | 2013-12-05 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of pemetrexed |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686365B2 (en) * | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| JP2013540104A (ja) * | 2010-07-28 | 2013-10-31 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 |
| US20150073000A1 (en) * | 2012-03-27 | 2015-03-12 | Fresenius Kabi Oncology Limited | Stable ready-to-use pharmaceutical composition of pemetrexed |
| EP2666463A1 (en) * | 2012-05-21 | 2013-11-27 | Synthon BV | Stabilized liquid composition comprising pemetrexed |
| WO2013179310A1 (en) * | 2012-05-31 | 2013-12-05 | Mylan Laboratories Limited | Stable aqueous compositions of pemetrexed |
| JP6099557B2 (ja) * | 2013-12-27 | 2017-03-22 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| KR101703980B1 (ko) * | 2013-12-30 | 2017-02-08 | 주식회사 삼양바이오팜 | 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법 |
| PT3206666T (pt) * | 2014-10-16 | 2020-03-11 | Synthon Bv | Composição farmacêutica líquida compreendendo pemetrexedo |
-
2016
- 2016-02-19 IL IL312427A patent/IL312427B2/he unknown
- 2016-02-19 MX MX2022009547A patent/MX2022009547A/es unknown
- 2016-02-19 KR KR1020247009885A patent/KR102794126B1/ko active Active
- 2016-02-19 CN CN201680084554.1A patent/CN109152778B/zh active Active
- 2016-02-19 MX MX2018010037A patent/MX2018010037A/es unknown
- 2016-02-19 KR KR1020187027212A patent/KR20180132643A/ko not_active Ceased
- 2016-02-19 AU AU2016393213A patent/AU2016393213B2/en active Active
- 2016-02-19 JP JP2018544196A patent/JP2019505561A/ja not_active Withdrawn
- 2016-02-19 CA CA3014755A patent/CA3014755C/en active Active
- 2016-02-19 IL IL301291A patent/IL301291A/he unknown
- 2016-02-19 WO PCT/US2016/018703 patent/WO2017142556A1/en not_active Ceased
- 2016-02-19 EP EP16890851.5A patent/EP3416646A4/en active Pending
-
2018
- 2018-08-15 IL IL261179A patent/IL261179B/he unknown
-
2022
- 2022-02-15 IL IL290647A patent/IL290647B2/he unknown
-
2023
- 2023-04-04 AU AU2023202089A patent/AU2023202089B2/en active Active
-
2025
- 2025-08-29 AU AU2025223868A patent/AU2025223868A1/en active Pending
- 2025-10-28 IL IL324306A patent/IL324306A/he unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080139810A1 (en) * | 2006-08-14 | 2008-06-12 | Jonathan Busolli | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid |
| WO2013179248A1 (en) * | 2012-05-30 | 2013-12-05 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of pemetrexed |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022009547A (es) | 2022-09-09 |
| EP3416646A1 (en) | 2018-12-26 |
| IL261179A (he) | 2018-10-31 |
| CN109152778B (zh) | 2021-08-10 |
| CN109152778A (zh) | 2019-01-04 |
| AU2023202089A1 (en) | 2023-06-01 |
| IL290647A (he) | 2022-04-01 |
| KR20240049356A (ko) | 2024-04-16 |
| AU2025223868A1 (en) | 2025-09-18 |
| IL290647B2 (he) | 2023-08-01 |
| AU2016393213A1 (en) | 2018-10-04 |
| AU2023202089B2 (en) | 2025-05-29 |
| IL301291A (he) | 2023-05-01 |
| CA3014755C (en) | 2023-11-14 |
| WO2017142556A1 (en) | 2017-08-24 |
| EP3416646A4 (en) | 2019-09-04 |
| IL290647B1 (he) | 2023-04-01 |
| KR20180132643A (ko) | 2018-12-12 |
| IL324306A (he) | 2025-12-01 |
| IL312427B1 (he) | 2025-12-01 |
| JP2019505561A (ja) | 2019-02-28 |
| AU2016393213B2 (en) | 2022-03-31 |
| KR102794126B1 (ko) | 2025-04-11 |
| IL261179B (he) | 2022-03-01 |
| CA3014755A1 (en) | 2017-08-24 |
| IL312427A (he) | 2024-06-01 |
| MX2018010037A (es) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (he) | פורמולציות | |
| GB2551985B (en) | Novel formulation | |
| IL273282A (he) | פורמולציות של ניראפריב | |
| IL269630A (he) | פורמולציות של ניראפריב | |
| IL269621A (he) | פורמולציות של ניראפריב | |
| IL265609A (he) | פורמולציות חדשות | |
| GB201607918D0 (en) | Novel formulations | |
| GB201419091D0 (en) | Formulations | |
| GB201419261D0 (en) | Formulations | |
| ES2873376T5 (en) | Maropitant formulation | |
| GB201608356D0 (en) | Formulation | |
| ZA201806530B (en) | Phosphaplatin liquid formulations | |
| GB201509891D0 (en) | Formulation | |
| GB201707615D0 (en) | Formulation | |
| IL290647B1 (he) | ניסוחים פמטרקס | |
| GB201504482D0 (en) | Novel formulations | |
| PL3559185T3 (pl) | Preparat nabłyszczający | |
| GB201621277D0 (en) | Formulations | |
| GB201618110D0 (en) | Formulations | |
| GB201616366D0 (en) | Formulations | |
| GB201615754D0 (en) | Formulations | |
| GB201418555D0 (en) | Pemetrexed formulations | |
| HK40003128A (en) | Pemetrexed formulations | |
| GB201617866D0 (en) | Novel formulations | |
| GB201616509D0 (en) | Novel formulations |